Tab Montek lc is safe in pregnancy

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Tab Montek LC contains Montelukast 10 mg + Levocetirizine 5 mg.
Here is what the evidence says about its use in pregnancy:

Montelukast (Leukotriene Receptor Antagonist)

Generally considered safe / most likely compatible with pregnancy, with the following caveats:
  • Animal studies show no teratogenicity for montelukast, and it can be continued in patients who have previously responded well to it.
  • Human data are limited, but use has not been associated with an increase in congenital anomalies in the studies available (including a large Danish cohort study).
  • It is classified as an alternative treatment for mild persistent asthma and an adjunctive option for moderate-to-severe persistent asthma during pregnancy.
  • Both montelukast and zafirlukast are considered "most likely compatible" with pregnancy and lactation; zileuton is the one leukotriene agent to avoid.
— Creasy & Resnik's Maternal-Fetal Medicine, p. 1412; Dermatology 2-Volume Set 5e; Murray & Nadel's Respiratory Medicine; Harrison's Principles of Internal Medicine 22e

Levocetirizine (Second-Generation Antihistamine)

  • Considered a pregnancy category B agent by the FDA.
  • Cetirizine and levocetirizine are among the antihistamines of choice in pregnant women (along with loratadine and budesonide for rhinitis management).
  • Preferred over first-generation (sedating) antihistamines during pregnancy.
— Cummings Otolaryngology Head and Neck Surgery

Bottom Line

ComponentPregnancy Safety
MontelukastMost likely compatible; limited human data but reassuring animal data and cohort studies
LevocetirizineFDA Category B; preferred antihistamine in pregnancy
Tab Montek LC is generally considered acceptable in pregnancy, particularly when treating asthma or allergic rhinitis where the benefit of controlling the condition outweighs the theoretical risk. However:
  • It should be used only when clinically necessary.
  • The prescribing physician should weigh the risk of poorly controlled asthma (which carries its own fetal risks — preterm birth, IUGR, hypoxia) against any theoretical drug risk.
  • Inhaled corticosteroids (budesonide, fluticasone) remain the first-line preferred agents for asthma control in pregnancy; Montek LC is an add-on or alternative.
  • Always defer to the treating obstetrician for final prescribing decisions.
This is a shared conversation. Sign in to Orris to start your own chat.